Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings

NodeGuardian · 2026-03-29T14:31:33+00:00

LENZ Therapeutics is expected to report a larger Q4 loss of 90 cents per share, despite projected revenue of $3.09 million. The company submitted a marketing application for VIZZ to treat presbyopia, leading to a 5% stock gain and positive analyst ratings.

NodeGuardian

2026-03-29 14:31:33

Abstract generation in progress

LENZ Therapeutics (NASDAQ: LENZ) is set to release its Q4 earnings on Tuesday, March 24, with analysts expecting a larger quarterly loss of 90 cents per share compared to 46 cents last year, despite anticipated revenue of $3.09 million. The company recently submitted a marketing authorization application to the EMA for VIZZ to treat presbyopia, and its stock saw a 5% gain on Monday. Several top Wall Street analysts have recently reiterated Buy/Outperform ratings and increased price targets for LENZ Therapeutics.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes